Skip Nav Destination
Issues
1 April 2019
-
Cover Image
Cover Image
ABOUT THE COVER
Currently, the recommended therapy for muscle-invasive urothelial cancer includes radical cystectomy with or without chemotherapy. In an attempt to develop an organ-sparing therapy, Berndt-Paetz and colleagues demonstrate the use of photodynamic therapy (PDT) in an orthotopic rat model. PDT with the near-infrared photosensitizer Tetrahydroporphyrin-Tetratosylat generated inflammation (at center) in the urothelial tumor (top right corner) without damaging the surrounding urothelium (lower left), submucosal tissue (lower left), or bladder smooth muscle (upper left). Their results suggest PDT is worthy of clinical consideration in muscle-invasive urothelial cancer. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Hiroki Irie; Kimihiro Ito; Yayoi Fujioka; Kei Oguchi; Akio Fujioka; Akihiro Hashimoto; Hirokazu Ohsawa; Kenji Tanaka; Kaoru Funabashi; Hikari Araki; Yuichi Kawai; Tadashi Shimamura; Renu Wadhwa; Shuichi Ohkubo; Kenichi Matsuo
Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model
Mandy Berndt-Paetz; Philipp Schulze; Philipp C. Stenglein; Annett Weimann; Qiang Wang; Lars-Christian Horn; Yasser M. Riyad; Jan Griebel; Ralf Hermann; Annegret Glasow; Jens-Uwe Stolzenburg; Jochen Neuhaus
Author Choice
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Remco Nagel; Ana Teresa Avelar; Nanne Aben; Natalie Proost; Marieke van de Ven; Jan van der Vliet; Miranda Cozijnsen; Hilda de Vries; Lodewyk F. A. Wessels; Anton Berns
Cancer Biology and Translational Studies
CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma
Gargi Maity; Arnab Ghosh; Vijayalaxmi Gupta; Inamul Haque; Sandipto Sarkar; Amlan Das; Kakali Dhar; Sneha Bhavanasi; Sumedha S. Gunewardena; Daniel D. Von Hoff; Sanku Mallik; Suman Kambhampati; Sushanta K. Banerjee; Snigdha Banerjee
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer
Georgios Kallifatidis; Diandra K. Smith; Daley S. Morera; Jie Gao; Martin J. Hennig; James J. Hoy; Richard F. Pearce; Isha R. Dabke; Jiemin Li; Axel S. Merseburger; Markus A. Kuczyk; Vinata B. Lokeshwar; Bal L. Lokeshwar
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies
Joseph Tintelnot; Natalie Baum; Christoph Schultheiß; Friederike Braig; Marie Trentmann; Johannes Finter; William Fumey; Peter Bannas; Boris Fehse; Kristoffer Riecken; Kerstin Schuetze; Carsten Bokemeyer; Thies Rösner; Thomas Valerius; Matthias Peipp; Friedrich Koch-Nolte; Mascha Binder
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma
Marcel Trautmann; Magdalene Cyra; Ilka Isfort; Birte Jeiler; Arne Krüger; Inga Grünewald; Konrad Steinestel; Bianca Altvater; Claudia Rossig; Susanne Hafner; Thomas Simmet; Jessica Becker; Pierre Åman; Eva Wardelmann; Sebastian Huss; Wolfgang Hartmann
Author Choice
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Giulia Martini; Claudia Cardone; Pietro Paolo Vitiello; Valentina Belli; Stefania Napolitano; Teresa Troiani; Davide Ciardiello; Carminia Maria Della Corte; Floriana Morgillo; Nunzia Matrone; Vincenzo Sforza; Gianpaolo Papaccio; Vincenzo Desiderio; Mariel C. Paul; Veronica Moreno-Viedma; Nicola Normanno; Anna Maria Rachiglio; Virginia Tirino; Evaristo Maiello; Tiziana Pia Latiano; Daniele Rizzi; Giuseppe Signoriello; Maria Sibilia; Fortunato Ciardiello; Erika Martinelli
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
Anthony S. Fischl; Xiaoen Wang; Beverly L. Falcon; Rowena Almonte-Baldonado; Diane Bodenmiller; Glenn Evans; Julie Stewart; Takako Wilson; Philip Hipskind; Jason Manro; Mark T. Uhlik; Sudhakar Chintharlapalli; Damien Gerald; David C. Alsop; Laura E. Benjamin; Rupal S. Bhatt
Correction
Retraction
Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor
Shu-Chuan Weng; Yoko Kashida; Samuel K. Kulp; Dasheng Wang; Robert W. Brueggemeier; Charles L. Shapiro; Ching-Shih Chen
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds